Novo Nordisk finally launches semaglutide pen indicated for weight loss in Australia
The TGA says it is still unclear how Wegovy will affect supply of drugs such as Ozempic.
Novo Nordisk’s subcutaneous weight-loss drug Wegovy will hit Australian shelves this month, two years after it received TGA approval.
The once-weekly injectable semaglutide formulation will be available on private prescription from early August, at a cost of $260-$460 depending on dose, the company says.
It is indicated for weight management in adults with obesity (≥30kg/m2) or overweight (≥27kg/m2) and at least one weight-related comorbidity, such as hypertension, type 2 diabetes or high cholesterol.
It is also approved for use in children aged 12 or older with obesity and a body weight over 60kg.
